SCHEMBL757240

SCHEMBL757240

NCC(O)CC(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL757239 1.00
Hydrochloric Acid SCHEMBL1825390 0.97 CETP (0.43)
SCHEMBL8027929 0.81 HTT (0.33)
SCHEMBL20656259 0.78
SCHEMBL21199073 0.76 CETP (0.40)
SCHEMBL3699194 0.74 CETP (0.43)
SCHEMBL8619080 0.73
SCHEMBL12871330 0.73
SCHEMBL12821068 0.73
SCHEMBL10177 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154344-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
CN-110869374-B 2-oxo-1, 3-oxazolidinyl imidazothiadiazole derivatives UCB生物制药有限责任公司 2022-08-30 CN disclosed
CN-114025844-B Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-07-26 CN disclosed
CN-114025844-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-02-08 CN disclosed
EP-3938038-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-01-19 EP disclosed
US-11155565-B2 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives UCB Biopharma SRL 2021-10-26 US disclosed
EP-3652183-B1 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Biopharma SRL (BE) 2021-09-08 EP disclosed
US-10851073-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2020-12-01 US disclosed
US-20200299246-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2020-09-24 US disclosed
WO-2020186199-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2020-09-17 WO disclosed
US-20080113966-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-05-15 US disclosed
US-20080113966-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-05-15 US disclosed
US-20070287697-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2007-12-13 US disclosed
US-20070287697-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2007-12-13 US disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
EP-1802637-A1 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-07-04 EP disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
WO-2006044504-A1 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-04-27 WO disclosed
WO-1989011870-A1 USE OF SPECIAL AMINES TO PREVENT NITROSAMINE FORMATION MERCK PATENT GMBH (DE) 1989-12-14 WO disclosed
EP-0344564-A1 Utilisation of special amines or hindering nitrosamine production Eisenbrand, Gerhard, Prof. Dr. (DE) 1989-12-06 EP disclosed